Peak revenues for Eisai's perampanel to reach $193m by 2019, analysts believe
06:32 EDT 30 Jul 2012 | SCRIP
Some analysts believe that Eisai's novel epilepsy product perampanel (Fycompa) could reach peak revenues of $193m by 2019 'despite underwhelming clinical trial data and relatively late market entry'. Sarah Nightingale, a healthcare analyst at.....
Original Article: Peak revenues for Eisai's perampanel to reach $193m by 2019, analysts believe
More From BioPortfolio on "Peak revenues for Eisai's perampanel to reach $193m by 2019, analysts believe"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
